Skip to main content
. 2022 Mar 23;14(7):1639. doi: 10.3390/cancers14071639

Figure 6.

Figure 6

Orthotopic mouse model studies confirmed that shcircDGKD intercepts the sunitinib-pretreatment-induced RCC VM formation, reduces metastases, and improves survival. (a) Schematic diagram demonstrating orthotopic mouse model implanted with 786-O-Luc-Scr vs. 786-O-Luc-shcircDGKD cells pretreated with or without 1 μM sunitinib (STN). (b) Representative IVIS images of four groups of female nude mice at week 8. (c) CD31/PAS double staining comparison between blood vessels in kidney tissue and VM in tumor xenografts. (d–f) Comparisons of numbers of mice between four groups with VM (+) vs VM (−) (d), with positive metastasis [Meta (+)] vs. negative metastasis [Meta (−)] (e), and metastatic foci number per mouse (f). (g) The survival length comparison between the four groups of mice. Scale bar, 100 μm. Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.